Alto Neuroscience, Inc.

NYSE:ANRO

Biotechnology

Healthcare
$25.91 +1.84%

+$0.40 today

Market cap
$1.04B
Beta
1.25
P/E (TTM)
-9.8
EPS (TTM)
-$2.26
52W Low $2.15High $28.44

Volume 0.99M

Average 0.34M

ANRO Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Alto Neuroscience, Inc.NYSE: ANRO

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $184K rose 7.6% year over year, behind the +14.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 17.2% from the prior quarter. Over 3 fiscal years it compounded at +24.6% a year.

Context

  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +7.6% toward the trailing-twelve-month pace of +14.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$184K+17.2% QoQ
Last fiscal yearDec 2025
$661K+31.7% YoY
LTMMar 2026
$674K+14.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.6%——
1 year+31.7%——
3-year CAGR+24.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
661K USD
Year-over-year change
+31.7%
4-year CAGR
+46.1%

Depreciation & Amortization vs competitors

How ANRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +14.4% is the 5th highest of 9, against a peer median of +9.3%.
  • Over three fiscal years its annual growth of +24.6% compares with a peer median of -0.6%.
ANRO Competitors
Depreciation & Amortization for ANRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLLSCellectis S.A.LTM Mar 2026$19.68M USD-2.6%+3.0%28.9%
KRROKorro Bio, Inc.LTM Mar 2026$3.75M USD-7.8%+14.7%97.6%
DBVTDBV Technologies S.A.LTM Mar 2026$3.14M USD+14181.8%-37.6%—
ACIUAC Immune S.A.LTM Dec 2025CHF 2.5M CHF+15.5%+0.4%69.9%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$1.23M USD—+8.0%—
SLNSilence Therapeutics plcLTM Mar 2026$885K USD—-2.3%96.0%
ANROAlto Neuroscience, Inc.LTM Mar 2026$674K USD+14.4%+24.6%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$328K USD+19.3%-0.6%—
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$326K USD+176.0%——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$257.68K USD+3.1%-0.9%—
AMRNAmarin Corporation plcLTM Mar 2026$97.21K USD-103.3%-0.7%0.0%
Peer median (excluding ANRO) —+9.3%-0.6%69.9%

Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.19M)(27.71M)(36.31M)(61.43M)(63.24M)
Depreciation & Amortization145K342K373K502K661K
Deferred Income Tax00000
Stock-Based Compensation227K1.76M2.89M7.63M8.11M
Change in Working Capital(572K)4.58M(698K)4.06M33K
Accounts Receivables(1.29M)1.16M325K00
Inventory00000
Accounts Payables458K1.01M(632K)516K221K
Other Working Capital255K2.42M(391K)3.54M(188K)
Other Non-Cash Items125K632K291K1.81M2.67M
Operating Cash Flow(9.26M)(20.39M)(33.45M)(47.42M)(51.77M)
Capital Expenditures(680K)(732K)(470K)(2.08M)(24K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(680K)(732K)(470K)(2.08M)(24K)
Debt Repayment09.83M01.25M9.48M
Common Stock Issued7K43K181K137.58M50.7M
Common Stock Repurchased0000(167K)
Dividends Paid00000
Other Financing Activities(205K)(341K)(2.05M)(3.14M)67K
Financing Cash Flow31.69M43.79M68.13M135.69M60.08M
Effect of Forex Changes(50K)(24K)(8K)(11K)(30K)
Net Change in Cash21.7M22.64M34.2M86.18M8.26M
Free Cash Flow(9.94M)(21.13M)(33.92M)(49.5M)(51.79M)

Alto Neuroscience, Inc.

NYSE:ANRO

Intrinsic Alpha fair value

Locked

Current Price

$25.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.